You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 17, 2024

cyclophosphamide Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cyclophosphamide, and what generic alternatives are available?

Cyclophosphamide is a drug marketed by Alembic, Ani Pharms, Cipla, Hikma, Kanchan Hlthcare, Zydus Lifesciences, Amneal, Baxter Hlthcare, Hengrui Pharma, Sagent Pharms Inc, Sunny, Xgen Pharms, Avyxa Holdings, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma Speclts, Sandoz, and Roxane. and is included in twenty-three NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has twelve patent family members in nine countries.

The generic ingredient in CYCLOPHOSPHAMIDE is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cyclophosphamide

A generic version of cyclophosphamide was approved as cyclophosphamide by BAXTER HLTHCARE on May 21st, 2008.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for cyclophosphamide?
  • What are the global sales for cyclophosphamide?
  • What is Average Wholesale Price for cyclophosphamide?
Summary for cyclophosphamide
Drug patent expirations by year for cyclophosphamide
Drug Prices for cyclophosphamide

See drug prices for cyclophosphamide

Recent Clinical Trials for cyclophosphamide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The University of QueenslandPhase 3
University of AdelaidePhase 3
National Cord Blood NetworkPhase 2

See all cyclophosphamide clinical trials

Pharmacology for cyclophosphamide
Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Paragraph IV (Patent) Challenges for CYCLOPHOSPHAMIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CYCLOPHOSPHAMIDE Injection cyclophosphamide 2 g/10 mL 212501 1 2023-01-17
CYCLOPHOSPHAMIDE Injection cyclophosphamide 500 mg/2.5 mL and 1 g/5 mL 212501 1 2022-03-07

US Patents and Regulatory Information for cyclophosphamide

cyclophosphamide is protected by four US patents.

Patents protecting cyclophosphamide


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Stable ready to use cyclophosphamide liquid formulations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Formulations of cyclophosphamide liquid concentrate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avyxa Holdings CYCLOPHOSPHAMIDE cyclophosphamide SOLUTION;INTRAVENOUS 210852-003 Jun 7, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sunny CYCLOPHOSPHAMIDE cyclophosphamide INJECTABLE;INJECTION 215089-002 Oct 26, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eugia Pharma Speclts CYCLOPHOSPHAMIDE cyclophosphamide SOLUTION;INTRAVENOUS 210735-002 Aug 25, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Baxter Hlthcare Corp CYCLOPHOSPHAMIDE cyclophosphamide SOLUTION;INTRAVENOUS 217651-001 Jun 28, 2023 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eugia Pharma Speclts CYCLOPHOSPHAMIDE cyclophosphamide SOLUTION;INTRAVENOUS 210735-003 Nov 20, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Roxane CYCLOPHOSPHAMIDE cyclophosphamide TABLET;ORAL 040032-001 Aug 17, 1999 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for cyclophosphamide

See the table below for patents covering cyclophosphamide around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2016147362 ПРЕПАРАТЫ ЖИДКОГО КОНЦЕТРАТА ЦИКЛОФОСФАМИДА ⤷  Sign Up
Australia 2015256331 Formulations of Cyclophosphamide liquid concentrate ⤷  Sign Up
Canada 2948148 FORMULATIONS D'UN CONCENTRE LIQUIDE DE CYCLOPHOSPHAMIDE (FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE) ⤷  Sign Up
Japan 6516831 ⤷  Sign Up
European Patent Office 3139929 FORMULATIONS D'UN CONCENTRÉ LIQUIDE DE CYCLOPHOSPHAMIDE (FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE) ⤷  Sign Up
South Korea 20170008252 사이클로포스파미드 액상 농축 제제 (FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.